To order this 540+ page report, please visit this – https://www.rootsanalysis.com/reports/view_document/large-volume-wearable-injectors/238.html
Key Inclusions
An overview of current market landscape of the large volume wearable injectors available for delivery of insulin and non-insulin drugs, providing information on status of development and device specifications, such as type of device (patch pump / injector and infusion pump / injector), type of dose administered (basal, bolus and others), route of administration (subcutaneous and others), mode of injection (needle, needle / cannula and needle / catheter), storage capacity of the device, actuation mechanism (electromechanical, rotary pump, cell / expanded battery, pressurized gas, osmotic pressure and others), usability (disposable and reusable), availability of prefilled drug reservoir and availability of device connectivity. The report also features additional information on availability of prefilled insulin cartridges, availability of continuous glucose monitoring / blood glucose monitoring (CGM / BGM) systems, availability of Automated Insulin Delivery feature and type of remote control features (control within device / personal diabetes manager (PDM) / smartphone) in the insulin delivery devices.
A detailed competitiveness analysis of large volume wearable injectors based on various relevant parameters, such as supplier power (based on the experience / expertise of the developer) and product specifications (type of device, type of dose, storage capacity of the device, usability, route of administration, connectivity and availability of a continuous glucose monitoring / blood glucose monitoring (CGM / BGM) systems (in case of insulin devices).
Elaborate profiles of the prominent companies that develop large volume wearable injectors. Each company profile features a brief overview of the company, its financial information (if available), information on its product portfolio, recent developments and an informed future outlook. Additionally, the report includes tabulated profiles of wearable drug device combination products.
An analysis of the partnerships that have been inked by the stakeholders in this domain, during the period between 2015 and 2020, covering acquisitions, product development agreements, product integration agreements, technology integration agreements, distribution and supply agreements, commercialization agreements, clinical trial agreements, licensing agreements,
The report features inputs from eminent industry stakeholders, according to whom, large volume injectors are generally preferred for the delivery of biologics, which cannot be easily administered orally. The report includes detailed transcripts of discussions held with the following experts:
Mark Banister (CEO, Medipacs)
Michael Hooven (CEO, Enable Injections)
Jesper Roested (CEO, Subcuject)
Pieter Muntendam (Former President and CEO, scPharmaceuticals)
Menachem Zucker (Vice President and Chief Scientist, Elcam Medical)
Graham Reynolds (Vice President and General Manager, Biologics, West Pharmaceutical Services)
Mindy Katz (Director of Product, Sorrel Medical)
To request sample pages, please visit this – https://www.rootsanalysis.com/reports/238/request-sample.html
Contact Us:
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Gaurav.Chaudhary@rootsanalysis.com
